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Crystal Structure of a SEA Variant in Complex
with MHC Class II Reveals the Ability of SEA
to Crosslink MHC Molecules
SEI, SEJ, SEK, and SEL) as well as two individual
branches (SPE-H and TSST-1), according to biochemi-
cal structural characterization [4]. All these superanti-
gens are globular proteins of 22–29 kDa and contain
two domains with a remarkable structural conservation
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P.O. Box 124 (an N-terminal  barrel, a C-terminal  grasp motif, and
an  helices-spanning center), considering their low se-S-221 00 Lund
Sweden quence identity [4].
Crystal structures of superantigens in complex with2 Active Biotech Research AB
P.O. Box 724 MHC class II have shown that they either interact with
the  chain, as in SEB and TSST-1 [5, 6], or with the S-220 07 Lund
Sweden chain, in a zinc-dependent manner, as in SEH and SPE-C
[7, 8] of MHC class II. Both SEH and SPE-C coordinate
a zinc ion in a similar manner, with one aspartate and
one or two histidine residues. The zinc ion bridges His81Summary
on MHC class II, which is the third ligand (the fourth in
the case of SPE-C). SEA coordinates zinc in a similarAlthough the biological properties of staphylococcal
manner to SEH and SPE-C, using Asp227, His225, andenterotoxin A (SEA) have been well characterized,
His187, and is believed to interact with His81 on MHCstructural insights into the interaction between SEA
class II in a similar manner, as well [7–9]. Alanine substi-and major histocompatibilty complex (MHC) class II
tution studies have shown that SEA is able to interacthave only been obtained by modeling. Here, the crystal
with either the  chain or the  chain of MHC class IIstructure of the D227A variant of SEA in complex with
[10, 11]. SEA binds with its N-terminal domain, with lowhuman MHC class II has been determined by X-ray
affinity (10 M), to the  chain of MHC class II andcrystallography. SEAD227A exclusively binds with its
with its C-terminal domain, in a zinc-dependent manner,N-terminal domain to the  chain of HLA-DR1. The
with medium affinity (100 nM), to the  chain [10].ability of one SEA molecule to crosslink two MHC mol-
It is well established that superantigens, in general,ecules was modeled. It shows that this SEA molecule
and SEA, in particular, may be used clinically. Mostcannot interact with the T cell receptor (TCR) while a
extensive studies have been performed in the field ofsecond SEA molecule interacts with MHC. Because
cancer therapy [12]. Because of its low systemic toxicity,of its relatively low toxicity, the D227A variant of SEA
the SEAD227A variant is successfully used in clinical trialsis used in tumor therapy.
in the treatment of lung cancer patients [13]. Although
SEA is one of the most extensively studied superanti-
Introduction gens, no three-dimensional structure information of the
complex between SEA and MHC class II is currently
Superantigens are microbial toxins that activate the im- available.
mune system by binding as unprocessed molecules to We have crystallized the D227A variant of SEA in com-
major histocompatibility (MHC) complex class II [1] and plex with HLA-DR1 and determined the three-dimen-
T cell receptor (TCR) molecules [2]. They activate a large sional structure to 3.2 A˚ resolution using X-ray crystal-
fraction of human T cells (20 % of all T cells) and lography. The substitution of the zinc-coordinating
stimulate them to secrete inflammatory cytokines, such Asp227 to an alanine has been shown to reduce the
as interleukin-2 (IL-2), tumor necrosis factor- (TNF-), binding affinity to human MHC class II more than 1000-
and interferon- (IFN-). These properties are attributed fold [10]. The crystal structure shows that SEAD227A inter-to their unique ability to crosslink MHC class II and TCR acts with the  chain of HLA-DR1 with its N-terminal
by recognizing a specific subset of TCR Vs. Superanti- domain and that the interaction with the  chain of HLA-
gens are known to be involved in a number of diseases DR1 is completely abrogated. We also suggest a model
characterized by fever and shock and are important of the quaternary complex where one SEA molecule
virulence factors for two human commensal organisms, crosslinks two MHC class II molecules while interacting
Staphylococcus aureus and Streptococcus pyogenes, with TCR.
as well as for some viruses [3]. The bacterial superanti-
gens, streptococcal pyrogenic exotoxins (SPEs), strep- Results
tococcal mitogenic exotoxins (SMEZ), staphylococcal
enterotoxins (SEs), streptococcal superantigen (SSA), Overall Structure
and toxic shock syndrome toxin (TSST-1) can be divided The molecular complex investigated consists of the
into three genetic subfamilies (class 1, SPE-C, SPE-J, D227A variant of SEA (27 kDa), the extracellular do-
SPE-G, and SMEZ; class 2, SEB, SEC1, SEC2, SEC3, mains of HLA-DR1 (44 kDa) containing the  chain
SSA, SPE-A, and SEG; class 3, SEA, SEE, SED, SEH,
Key words: MHC class II; protein-protein interaction; SEA; staphylo-
coccal enterotoxin; superantigen; X-ray crystallography3 Correspondence: bjorn.walse@activebiotech.com
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Table 1. Crystal Data Collection and Structure Refinement
Statistics
Data Collection
Resolution range (A˚) 30–3.2
Rsym (%)a 10.1 24.6b
Completeness (%) 91.6 87.9b
Unique reflections, total 38,082 4,777b
Redundancy, total 3.1 2.8b
I/ 6.4 3.1b
Refinement Statistics
R factor (%) 24.5
Rfree (%)c 33.9
B factor (A˚2) 46.2
Water molecules 23
Model Statistics
Bond length rmsd (A˚) 0.009
Bond angles rmsd () 1.59
a Rsym  hi |I(h,i) 	 I(h )|/Ihi(h,i), where I(h,i) is the intensity of
the ith measurement of h and I(h ) is the corresponding average
value of all i measurements.
b Last shell, 3.2–3.37.
c Rfree was determined with 8% of all reflections.
Figure 1. Ribbon Representation of the DR1-SEAD227A Complex with
HLA-DR1, in Green, Ha-Peptide, in Red, and SEAD227A, in Yellow
lose their affinity for zinc as well as their ability to bind
HLA-DR1 in a zinc-dependent fashion. The N terminus(21 kDa) and the  chain (22 kDa), and the hemagglu-
tinin peptide (Ha-peptide), PKYVKQNTLKLAT. of SEA has been suggested to provide one of the coordi-
nates to the zinc ion [9]. This residue, Ser1, is seen inAlanine substitution studies have shown that SEA has
two binding sites for human MHC class II, one N-terminal the DR1-SEAD227A complex structure and is positioned in
such a way that it could coordinate a zinc ion. However,site and one C-terminal zinc-dependent site [10, 11]. We
have chosen to crystallize a variant of SEA in which residues 3–6 in the N-terminal region of SEAD227A are not
seen, possibly due to disordering of the protein.the C-terminal zinc-dependent site is believed to be
abrogated. In this way, we have been able to capture A second zinc site, which is situated between the two
domains of the protein, has been observed in SEA bythe complex in which SEA uses its low affinity site when
binding to HLA-DR1. The major interactions between X-ray crystallography [14]. Thermal denaturation also
shows that zinc ions can stabilize the structure ofSEAD227A and HLA-DR1 are between the N-terminal 
barrel of SEAD227A and thechain of HLA-DR1. The super- SEAD227A [15]. However, no such zinc site is detected in
the DR1-SEAD227A structure, although the crystallizationantigen binds to one side of HLA-DR1, outside the pep-
tide binding groove, and does not contact the peptide was performed in the presence of 1 mM ZnCl2. This
second zinc binding site may therefore only be relevant(Figures 1 and 2; Table 1).
The overall structure of SEAD227A in complex with HLA- at higher concentrations of zinc. A similar zinc site was
also observed in the crystal structure of SEC2, and itDR1 has minor conformational changes compared with
the uncomplexed structure of SEA [9]. The major differ- has been suggested to be important for SEC1 when
interacting with MHC class II [16, 17]. Two of theseence is in the C-terminal domain in the zinc binding area,
where no electron density for a zinc ion is seen in the corresponding and putative zinc coordinating ligands in
SEA, His114 and Glu39, have previously been substi-3.2 A˚ 2Fo 	 Fc map. This is expected, since Asp227 in
SEA is known to be one of the three zinc ligands, ac- tuted to investigate the consequence for MHC class II
binding [10]. Neither the MHC class II binding nor thecording to mutagenesis studies [10]. Hence, when
Asp227 is substituted to an alanine, the SEA molecules ability to mediate T cell cytotoxicity was affected, and,
Figure 2. Stereoview of the C Chain Repre-
sentation of the DR1-SEAD227A and DR1-SEB
Complexes
HLA-DR1 from both complexes has been su-
perimposed. Areas in SEB that are not de-
fined in the crystal structure are not dis-
played. HLA-DR1, green; antigenic peptide,
red; SEAD227A, yellow; SEB, cyan.
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Figure 3. Ribbon Representations of the Interfaces between (A) HLA-DR1, in Green, and SEAD227A, in Yellow, and (B) HLA-DR1, in Green, and
SEB, in Cyan, as Well as Electrostatic Interaction and Hydrogen Bond Pattern of Selected Residues in the Interface
therefore, we conclude that the proposed second zinc activation (IL-2 production) has earlier been shown by
substitution studies [21].site is not important for the interaction with MHC class
II, in accordance with the DR1-SEAD227A structure. The crystal structure of DR1-SEAD227A clearly demon-
strates that one SEA molecule cannot interact with bothThe overall HLA-DR1 structure in this complex is very
similar to the published uncomplexed structure of HLA- its N- and C-terminal sites with the same MHC class II
molecule at the same time. This is because the C-ter-DR1 [18]. This agrees well with other solved complexes
between superantigens and MHC class II, where no ma- minal domain of SEAD227A is oriented away from the HLA-
DR1 molecule and is therefore too far away to establishjor changes in the structures of the MHC class II mole-
cules have been reported [5, 7]. an interaction (Figure 1).
DiscussionThe Interface between SEAD227A and HLA-DR1
The total accessible area in the complex is 29,896 A˚2,
calculated with GRASP [19], with an interface burying In this study, the crystal structure of SEAD227A in complex
with HLA-DR1 was determined at 3.2 A˚ resolution.554 A˚2 and 567 A˚2 of the HLA-DR1 and SEAD227A solvent-
accessible surfaces, respectively [20]. The interface be- SEAD227A binds to the  chain of HLA-DR1 and does not
contact the presented Ha-peptide. The D227A substitu-tween SEAD227A and HLA-DR1 consists of a ridge of non-
polar residues (Phe47, Leu48, and His50) situated on tion of SEA prevents the superantigen from interacting
with thechain of HLA-DR1 through the zinc-dependentthe loop between the 1 and 2 strands of SEAD227A,
which protrudes their side chains into the cavity be- site on the C-terminal domain.
tween the 1 helix and the  sheet that creates the
peptide binding groove of HLA-DR1. The amino acids Comparison with SEB
The overall structure of the DR1-SEAD227A complex mim-creating the ridge, in particular, Phe47, interact with
several nonpolar amino acids (Leu60, Ile63, and Ala64) ics the binding between SEB and HLA-DR1, in general
[5, 22]. However, the contacting region between SEAD227Alocated on the 1 helix of HLA-DR1 as well as with Lys39
and Met36, situated on the loop between the 3 and 4 and HLA-DR1 is only around 70% of the contacting
region of DR1-SEB (burying 788 A˚2 and 764 A˚2 of thestrands on the  chain of HLA-DR1. In addition, Asp70
of SEAD227A makes a salt bridge with Lys39. A hydrogen HLA-DR1 and SEB solvent-accessible surfaces, respec-
tively). The major difference between the two superanti-bond is seen between His50 and Asp70, both on
SEAD227A, which possibly stabilizes the interface by di- gen-HLA-DR1 complexes is that the SEAD227A is partially
rotated away from the HLA-DR1 molecule comparedrecting Asp70 to Lys39 on HLA-DR1, hence facilitating
the salt bridge formation. Two hydrogen bonds are likely with SEB (Figure 2). The rotation is mainly due to move-
ment of the disulphide loop caused by a replacementto be formed between Gln46 and Gln95 on SEAD227A and
Gln18 and Gln57 on the  chain of HLA-DR1, respec- of Tyr94 in SEB, which stabilizes the DR1-SEB complex,
to the corresponding Ala97 in SEAD227A. In addition, Ser96tively. The interaction between Gln46 and Gln18 is close
to the hydrophobic interacting area between SEAD227A in SEB, also situated on the disulphide loop, contacts
HLA-DR1, as well. In the interface of DR1-SEB, there areand HLA-DR1 (described above), while the interaction
between Gln95 (SEAD227A) and Gln57 (HLA-DR1) is situ- seven hydrogen bonds between the molecules, while, in
the DR1-SEAD227A complex, there are only two hydrogenated between the disulphide loop of SEAD227A and the
1 domain of the  helix of HLA-DR1 (Figure 3A). The bonds. For instance, in the DR1-SEB structure, two hy-
drogen bonds are formed from Tyr89 and Tyr115 onimportance of Phe47 on SEA and Lys39 and Gln18 on
HLA-DR1 for complex formation as well as for T cell SEB to Lys39 of HLA-DR1 (Figure 3B). These are in close
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proximity to the salt bridge between Glu67 of SEB and using its N-terminal and C-terminal domains. This is
in agreement with previous results demonstrating thethe same lysine. In the DR1-SEAD227A structure, a similar
salt bridge is formed between Asp70 of SEAD227A and importance of simultaneous ligation of both the  chain
and the  chain of two different MHC class II moleculesLys39 of HLA-DR1, but the two corresponding residues
(Tyr92 and Tyr108), although structurally aligned with for optimal T cell response by SED and SEE in cell-
based studies [33].the two tyrosines in SEB, are too far from HLA-DR1 to
be able to form hydrogen bonds. This is due to a small
conformational change of the side chain of Lys39 (2 A˚
T Cell Activationmovement of the nitrogen; Figure 3) as well as a larger
Substitution studies have been performed with SEA tooverall distance between the SEAD227A and the HLA-DR1
explain the consequence of the two MHC class II bindingmolecules than in the DR1-SEB complex. The compara-
sites for optimal T cell activation. Eliminating the low-bly small contact region for the DR1-SEAD227A complex
affinity class II binding site had a stronger influence onis correlated to the ability for residues on SEAD227A to
the Vprofile than did the removal of the medium-affinitymake van der Waals contacts with HLA-DR1. Hence, this
zinc-dependent site [28]. However, the potency of SEAis in full agreement with SEB binding 40-fold stronger to
to mediate T cell cytotoxicity is more affected by elimi-MHC class II [10, 23].
nating the zinc site [10]. Through the use of the structure
solved here, it was possible to model the quaternary
Interaction with Other MHC Molecules complex (MHC2-SEA1-TCR1) to find out how the cross-All published complex structures between superanti- linking of two MHC class II molecules by one SEA mole-
gens and MHC molecules have so far been with HLA- cule affects the interaction interface between APC and
DR molecules [5–8]. However, it has been shown that the T cell. The model was made by combining the cross-
the SSA superantigen binds HLA-DQ molecules on the linking model of SEA, described above, and a model of
cell surface [24]. A sequence comparison between HLA- SEA interacting with the  chain of TCR, based on the
DR, HLA-DQ, and HLA-DP shows that Lys39 in the  structure of the SEB-TCR complex (1SBB) [34], since it
chain of HLA-DR1, which is important for the low-affinity has been shown that SEA and SEB have overlapping
site between SEA and HLA-DR1, is conserved between TCR binding regions [35, 36]. Finally, the TCR-HLA-DR1
the different HLA-DR, -DP, and -DQ molecules. In addi- complex (1FYT) [37] was used to model the  chain of
tion, His81 on the  chain of HLA-DR1, which is the most TCR, which is not present in the SEB-TCR structure
important amino acid for the zinc-dependent medium- (Figure 4A). The overall geometry of the complex, with
affinity site between SEA and HLA-DR1, is also con- the C termini of MHC and TCR in opposite directions,
served between all three HLA molecules [25]. Hence, results in a very plausible contacting region between
SEA is very likely to be presented by both HLA-DQ and APC and the T cell (Figure 4A). The overall distance
HLA-DP in a similar way to HLA-DR, which is supported between the C termini is in agreement with the MHC-
by cell-based studies [26]. TCR complex (130 A˚) [37]. This clearly shows that it
is possible for TCR and MHC to interact in the quaternary
complex formation, as has previously been suggestedCrosslinking of MHC
The ability of SEA to simultaneously bind two separate [38] (Figure 4A). The model presented here rules out the
possibility for one MHC class II molecule to simultane-MHC class II molecules, utilizing both the low- and me-
dium-affinity sites, results in a high-affinity interaction ously interact with TCR and with two SEA molecules.
The V chain of TCR and the second SEA molecule thatwith MHC class II. The DR1-SEAD227A structure demon-
strates that SEA is able to crosslink two MHC class II interacts with the  chain of MHC class II will totally
overlap (Figure 4B). However, trimeric complexes (SEA2-molecules because the C-terminal domain is directed
away from the bound HLA-DR1 and is completely free MHC1) have been seen in solution [39], and these com-
plexes might appear on the cell’s surface, but the firstto interact with another MHC class II molecule with no
steric hindrance. The ability of SEA to use both sites SEA molecule will not be able to interact with the TCR
because of the overlap between the second SEA andfor MHC class II binding has earlier been shown to be
important for optimal T cell activation and cytokine in- TCR (Figure 4). Consequently, it is not possible for SEA
and MHC class II to oligomerize and create chains ofduction [27–29]. The interaction between the C-terminal
domain of SEA and HLA-DR1 is suggested to be very complexes on the cell surface for an optimal T cell acti-
vation.similar to the interaction between SEH and HLA-DR1.
This is supported by the fact that both superantigens The model for crosslinking two MHC molecules by
SEA suggests a mechanism where the medium-affinityhave a zinc-dependent interaction with the  chain of
HLA-DR1 as well as an interaction with the antigenic zinc-dependent site is the first and most important inter-
action between SEA and MHC class II. When that bind-peptide [7, 11, 30, 31]. A model of SEA crosslinking
two MHC class II molecules was created by performing ing has been established, SEA binds a second MHC
class II molecule on the cell surface using its low-affinitystructural alignment between the complexes DR1-
SEAD227A and DR1-SEH (1HXY) [7], superimposing the site to induce an optimal T cell response (SEA1-MHC2).
As a consequence of crosslinking, there must be moreHLA-DR1 molecules to model the medium-affinity site
between SEA and HLA-DR1 (Figure 4). Sequence align- MHC class II molecules present than SEA on the cell
surface, which agrees well with data where less thanment with Clustal W [32] shows that, in addition to SEA,
there are three other bacterial superantigens, SED, SEE, 0.3 % of the cell surface MHC class II needs to be
occupied by SEA to generate an optimal T cell responseand SEJ, that may crosslink MHC class II molecules by
Crystal Structure of MHC Class II-SEAD227A Complex
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Figure 4. Structural Overview of Modeled
Complexes
(A) Model of the quaternary complex, which
illustrates SEA (yellow) crosslinking two HLA-
DR1 molecules (green) as well as interacting
with the T cell receptor (blue). The insertion
illustrates the ability of the quaternary com-
plex to create a regular distance between the
APC and the T cell.
(B) Model of an HLA-DR1 (green) molecule
presenting two SEA (yellow) molecules,
where the first SEA molecule will be unable
to interact with TCR because of the V chain
of TCR and the second SEA molecule will
totally overlap, according to Figure 4A.
[40]. However, SEA may be presented to TCR, although low-affinity sites interact with MHC class II molecules
[28]. Hence, the zinc-dependent site is important for SEAless optimally, using only its medium-affinity site. In this
case there will be no direct interaction between TCR to find the MHC class II molecules on the cell surface of
APCs, while the low-affinity site is more important forand MHC, according to the quaternary complex (MHC2-
SEA1-TCR1) model. It has been demonstrated that T cells activating a broad V repertoire of T cells.
activated when SEA is presented only by its medium-
affinity site are also activated by SEA in the absence of Tumor-Targeted Superantigens
Bacterial toxins have been known since the beginningMHC class II molecules [41]. This concludes that, when
SEA is suboptimally presented by MHC, no interaction of the twentieth century to have antitumor effects [42].
An approach of superantigen-based tumor therapy hasbetween MHC and TCR will occur. The suboptimal pre-
sentation of SEA will lead to stimulation of a more selec- been developed where a superantigen is fused to frag-
ments of tumor-reactive monoclonal antibodies [43]. Intive TCR V repertoire than when both the medium- and
Structure
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2.5 g of (NH4)2SO4, 3 g of KH2PO4, 2 g of K2HPO4, 0.5 g of trisodiumthis way, the T cells can be directed to MHC class II-
citrate, 1 g of MgSO4 · 7H2O, 0.05 g of kanamycin, 12 g of glucose,negative tumor cells and kill the target cells [12]. Initial
and 1 ml of trace element solution [47], however, without Na2MoO4 ·clinical studies used wild-type SEA [44, 45], but, be-
2H2O. The cells were grown to an Abs620 of 2–3, and 10 ml of thecause of toxicity, there has been a need to find novel cultivation medium was used to inoculate a 1 liter fermenter (Belach
variants. SEAD227A is successfully used in fusion with the Bioteknik, Sweden) with a starting volume of 800 ml growth medium.
This medium contained (per liter) 2.5 g of (NH4)2SO4, 9 g of KH2PO4,Fab moiety of the tumor-reactive antibody 5T4 in phase
6 g of K2HPO4, 0.5 g of trisodium citrate, 1 g of MgSO4 · 7H2O, 0.05II clinical trials [13]. The advantage of the mutant, com-
g of kanamycin, 20 g of glucose, and 1 ml of trace element solution,pared with wild-type SEA, is a reduced accumulation of
as above. The pH was kept constant at 7.0 by titration of 25%superantigen in MHC class II-expressing organs, leading
NH3, the aeration was 1 l/min, and the temperature was 25C. Theto reduced systemic shock [46]. The crystal structure dissolved O2 was kept at 30% by regulating the agitation from 400
described here explains the ability of SEAD227A to bind rpm to 2000 rpm during the batch phase and by regulating the feed
of glucose (60% w/v) during the fed batch phase. After cultivationMHC class II in a more moderate fashion than does wild-
the cells were removed by centrifugation at 6 000 
 g for 45 mintype SEA, which is desirable for activating a sufficient
at 4C, and the clarified medium containing SEAD227A was storedamount of T cells to evoke an antitumor response, but
at	20C prior to purification. The pH of the medium was adjusted tothis prevents the superantigen from homing in on other
6.0 and applied to a HiLoad 26/10 SP Sepharose column (Amersham
organs than the tumor. Pharmacia Biotech). The sample was eluted with a linear gradient
of 0–400 mM of NaCl with a running buffer containing 10 mM KH2PO4
and 0.025% Tween-20 at pH 6.0. The yield was 80 mg/l of growthBiological Implications
medium.
The extracellular parts of the HLA-DR1  chain (DR*0101) and Superantigens are a group of highly potent immunostim-
chain (DRB1*0101) were both expressed in E. coli as inclusion bod-
ulatory proteins of bacterial or viral origin that bind MHC ies and refolded in the presence of Ha-peptide by a standard dilution
class II and activate a large number of T cells. Activation protocol as described in Petersson et al. [7].
SEA was transferred to TBS (25 mM Tris and 150 mM NaCl [pHresults in a vigorous T cell proliferation and production
7.4]) with a PD-10 column, while the folded HLA-DR1 complex wasof cytokines. Determining the structural basis on presen-
exchanged to 30 times-diluted TBS. The protein samples were con-tation of superantigens by MHC class II, as well as how
centrated, SEA with Centriprep-10 (Amicon, Beverly, MA) and HLA-the ability of T cell activation is influenced by the presen-
DR1, 30 times, by slow evaporation.
tation, is essential to understanding the biological prop-
erties of superantigens. While SEA is one of the best Crystallization and Data Collection
biologically characterized superantigens, the structural Concentrated HLA-DR1 peptide complex (3.2 mg/ml, according to
UV absorbance measurements at 280 nm) was mixed with highlyknowledge of its MHC interaction is based on other
concentrated SEAD227A (10 mg/ml, according to UV absorbance mea-superantigens, like SEB. The structure presented here
surements at 280 nm) to a final concentration of 4.5 mg/ml proteinreveals how SEA interacts with MHC class II through its
(molar ratio 1:1) in the presence of 1 mM ZnCl2. Crystals were grownN-terminal domain. In contrast to other related superan- with vapor diffusion by mixing 1.5 l protein solution with 1.5 l well
tigens, such as SEB and SEH, SEA is known to bind and solution containing 0.2 M (NH4)2SO4, 0.1 M MES, and 24% (w/v)
crosslink MHC class II bivalently, using both its N-ter- polyethylene glycol monomethyl ether 5000 (pH 6.5). The crystals
grew in 3 weeks, belonged to space group P212121, with cell dimen-minal and C-terminal domains. In this study, the C-ter-
sions a  52.0 A˚, b  75.8 A˚, c  198.1 A˚,       90, andminal interaction with MHC class II has been abrogated
contained one complex per asymmetric unit. The crystals were flash-by an alanine substitution to capture the low-affinity
frozen in 0.2 M (NH4)2SO4, 0.1 M MES, 24% (w/v) polyethylen glycolinteraction with MHC. The crosslinking of MHC mole- monomethyl ether 5000 (pH 6.5), and 20 % (v/v) glycerol.
cules is essential for SEA to be able to activate a large A data set was collected at beamline I711 at the MAX laboratory
population of T cells and, hence, become one of the in Lund, Sweden, with a MarCCD detector. The data set was evalu-
ated in MOSFLM [48] and scaled with the CCP4 suite of programsmost potent superantigens. Crosslinking also stimulates
[49]. Statistics on data collection and quality are presented inantigen-presenting cells to secrete inflammatory cyto-
Table 1.kines. In addition, the low-affinity site is here shown to
be important for the proper presentation of SEA to TCR,
Structure Determination and Refinement
since SEA’s ability to stimulate a broad population of T The structure of the DR1-SEAD227 complex was solved by molecular
cells is reduced if this site is eliminated. Superantigens replacement technique with the program AMORE [50], with SEA,
have, for a long time, been known to have antitumor 1ESF [9], and the HLA-DR1 peptide complex, 1DLH [18], as search
models. Model building and checking of electron density maps wereeffects. The variant studied here has shown very promis-
done with Xtalview [51], and all refinement was performed with CNSing results in clinical trials because of its ability to bind
[52]. The final model includes A3–A182 in the  chain and B3–B190 inMHC in a more moderate fashion. This leads to a re-
the  chain of HLA-DR1, C306–C318 in the Ha-peptide, and residues
duced accumulation of superantigen in MHC-express- D1–D233 in SEAD227A. The final R factor (Rfree) is 0.245 (0.339), and
ing organs, leading to reduced systemic shock com- good geometry in the model indicates a well-determined structure.
pared with wild-type SEA. More than 97% of all residues are in the most favored or allowed
regions in the Ramachandran plot, and only 0.7% are in disallowed
regions, according to the PROCHECK program [53]. Details of theExperimental Procedures
structure are given in Table 1.
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